KRAS and colorectal carcinoma: The results indicated that DDX3 loss in K-Ras mutant CRC further activated the MAPK pathway and that targeting this pathway partially inhibited the proliferation and metastasis of tumor cells caused by DDX3 loss in K-Ras mutant CRC.